The BRCA1 gene encodes a tumor suppressor that has been implicated in hereditary forms of breast and ovarian cancer. During S phase of the cell cycle, BRCA1 polypeptides are found in discrete nuclear bodies (`BRCA1 nuclear dots') together with HsRad51, a human homolog of the E. coli recA protein, and BARD1, a protein that interacts with BRCA1 to form a stable heterodimer. BARD1 is structurally similar to BRCA1 in that both molecules harbor an amino-terminal RING domain and two carboxy-terminal BRCT domains. Here we describe the amino acid sequence and expression pattern of murine Bard1. A comparison of the mouse and human sequences reveals that the recognizable protein motifs of BARD1 are well conserved, including the RING domain, the three tandem ankyrin repeats, and, to a lesser extent, the two BRCT domains. However, the remaining sequences of BARD1 display a markedly lower degree of phylogenetic conservation, comparable to those reported for BRCA1 and BRCA2. Moreover, murine Bard1 retains the ability to associate in vivo with BRCA1, and its expression pattern in adult mice mirrors that of Brca1, with elevated levels of RNA transcripts found in the testes and spleen. These data suggest that BRCA1 and BARD1 have co-evolved to participate in a common pathway of tumor suppression.
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Keywords: BRCA1; breast cancer; RING domain; BRCT domain; tumor suppressor Almost half the families aicted with hereditary breast cancer harbor germline mutations of the BRCA1 gene (Hall et al., 1990; Miki et al., 1994) . Since neoplastic development in BRCA1 mutation carriers is accompanied by loss or inactivation of the wildtype allele, the BRCA1 protein is likely to function as a tumor suppressor (Smith et al., 1992) . Although the biochemical properties of BRCA1 are poorly understood, recent studies have shown that its subcellular distribution is cell cycle-dependent (Chen et al., 1995 (Chen et al., , 1996 Scully et al., 1996 Scully et al., , 1997a Thomas et al., 1996; Runer and Verma, 1997; Thakur et al., 1997; Wilson et al., 1997) . BRCA1 polypeptides are diusely distributed in the nuclei of resting cells and G1 proliferating cells. However, when proliferating cells enter S phase, these polypeptides accumulate within discrete nuclear foci (the`BRCA1 nuclear dots') together with HsRad51, a mammalian homolog of the bacterial recA protein. Since recA and its eukaryotic counterparts have been implicated in DNA repair, it was proposed that BRCA1 normally serves to maintain genomic stability and that the ability of BRCA1 to suppress tumor formation is a re¯ection of its role in DNA repair (Scully et al., 1997a,b) .
BARD1 is likely to play a critical role in BRCA1-mediated tumor suppression. BARD1 and BRCA1 have a similar con®guration of amino acid motifs, with a RING domain at the amino-terminus and two tandem copies of the BRCT domain at the carboxyterminus (Wu et al., 1996) . In vivo, these proteins exist as a heteromeric protein complex, the formation of which is completely abolished by tumor-associated missense mutations in the RING domain of BRCA1 (Wu et al., 1996) . Since germline carriers of these mutations have a pronounced susceptibility to breast and ovarian cancer, the interaction between BARD1 and BRCA1 may be essential for the tumor suppression activity ascribed to BRCA1. Indeed, rare alterations of the BARD1 gene have been uncovered in primary tumors of breast, ovarian, and uterine tissues, suggesting that BARD1 mutations may themselves be contributing factors in the development of some human carcinomas (Hoa Thai et al., 1998) . Recently, immunostaining experiments have shown that BARD1, BRCA1 and HsRad51 polypeptides colocalize to the same nuclear bodies ± the`BRCA1 nuclear dots' ± during S phase of the cell cycle Scully et al., 1997a,b) . Moreover, when S phase cells sustain DNA damage, the BRCA1 nuclear dots disperse (Scully et al., 1997a; Thomas et al., 1997) and, in at least some cells, BARD1-, BRCA1-and HsRad51-staining reappears in distinct nuclear structures that represent sites of damaged, replicating DNA (Scully et al., 1997a) . Taken together, these observations suggest that BARD1 and BRCA1 are functionally-related proteins that, in association with HsRad51, participate in the cellular response to DNA damage.
Recent studies have uncovered striking parallels between the properties of BRCA1 and those of BRCA2, another tumor suppressor that is also inactivated in many cases of hereditary breast cancer (Wooster et al., 1994 (Wooster et al., , 1995 Tavtigian et al., 1996) . Although the proteins encoded by these genes do not share appreciable sequence homology, their expression patterns during cell cycle progression are almost indistinguishable (Rajan et al., 1996 (Rajan et al., , 1997 Spillman and Bowcock, 1996; Vaughn et al., 1996; Bertwistle et al., 1997; Wang et al., 1997) . Furthermore, BRCA2 polypeptides have been shown to associate in vivo with HsRad51 (Mizuta et al., 1997; Wong et al., 1997; Chen et al., 1998; Katagiri et al., 1998) , the same protein that localizes to the BRCA1-staining nuclear dots of S phase cells (Scully et al., 1997a,b) . Although the subcellular distribution of BRCA2 polypeptides has not been evaluated by direct immunostaining, Western analysis of subcellular fractions shows that BRCA2 is predominantly a nuclear protein (Bertwistle et al., 1997) . This, together with its ability to interact with HsRad51, suggests that BRCA2 may also reside in the same nuclear structures as BRCA1, HsRad51 and BARD1.
An interesting feature of BRCA1 and BRCA2 is their poor degree of evolutionary conservation. For example, the mouse and human counterparts of these proteins share less than 60% amino acid identity, a level of phylogenetic conservation that is remarkably low ± especially when compared with those of other known tumor suppressors (Abel et al., 1995; Bennett et al., 1995; Lane et al., 1995; Sharan et al., 1995; Szabo et al., 1996; Connor et al., 1997b; McAllister et al., 1997; . Moreover, yeast orthologs of the BRCA1 and BRCA2 genes are not found within the complete nucleotide sequence of the Figure 1 An alignment of the amino acid sequences of mouse and human BARD1. The potential initiator methionines (residues 1 and 20 of murine Bard1) are marked with vertical arrows. Sequences corresponding to the RING motif (murine residues 40 ± 84), the three tandem ankyrin repeats (residues 415 ± 513), and the two tandem BRCT domains (residues 593 ± 765) are highlighted. The Q564H mutation of human BARD1 is also indicated (Hoa Thai et al., 1998) . The sequences were aligned by introducing gaps to maximize amino acid sequence identity; the values for amino acid identity were then calculated by considering each gap as a single mismatch. The composite sequence of BARD1 cDNA has been deposited in the GenBank database (accession no. AF057157)
S. cerevisiae genome. Yet, BRCA1 and BRCA2 associate in vivo with HsRad51 (Mizuta et al., 1997; Scully et al., 1997a,b; Wong et al., 1997; Chen et al., 1998; Katagiri et al., 1998) , a highly conserved protein with obvious counterparts in not only yeast (Rad51) but also in bacteria (RecA) (Karlin and Brocchieri, 1996) . Since BARD1 polypeptides are likely to function in the same biochemical pathway as BRCA1, we sought to compare the evolutionary stability of BARD1 with that of BRCA1, BRCA2 and HsRad51. Therefore, a lEXlox cDNA library prepared from an 11-day-old whole mouse embryo (Novagen, Inc.) was screened by hybridization with radiolabeled fragments of human BARD1 cDNA. Two independent hybridizing clones were isolated (mB-12ex and mB-22ex), each of which contained sequences encoding a carboxy-terminal segment of the mouse Bard1 polypeptide (amino acid residues 405 ± 765 and 87 ± 765, respectively). A cDNA fragment encoding the full-length protein (mB-2-2; residues 1 ± 765) was then obtained by screening a mouse acinar cell cDNA library with murine sequences from the mB-22ex insert. The alignment in Figure 1 shows that the mouse and human orthologs of BARD1 share *70.4% amino acid identity. Higher levels of conservation are found within the known protein domains of BARD1; namely, the amino-terminal RING motif (86.7% identity), the three internal ankyrin repeats (90.1%), and the two carboxyterminal BRCT domains (79.8%).
To evaluate the expression pattern of Bard1, steady-state levels of Bard1 transcripts were determined by Northern analysis of polyadenylated RNA derived from dierent tissues of adult mice. As illustrated in Figure 2a , Bard1 transcripts of approximately 6.0 and 3.0 kilobases are especially prevalent in RNA from spleen and testes (lanes 3 and 8, respectively), but not from heart, brain, lung, liver, skeletal muscle or kidney. The same expression pattern was obtained upon hybridization with pE18, a cDNA probe containing codons 8 ± 301 of mouse Brca1 (Bennett et al., 1995) ; in accord with previous reports (Abel et al., 1995; Bennett et al., 1995; Lane et al., 1995; Zabludo et al., 1996; Blackshear et al., 1998) , this probe detects a major polyadenylated RNA species of 7.5 kilobases in the spleen and testes of adult mice (Figure 2b ). The abundance of Bard1 and Brca1 transcripts in spleen and testes is especially striking given that these samples displayed the lowest levels of hybridization with the GAPDH control (Figure 2c ; lanes 3 and 8).
Human BARD1 was originally identi®ed on the basis of its ability to associate in vivo with BRCA1 (Wu et al., 1996) . A minimal sequence required for the interaction has been localized to residues 26 ± 142, a segment of human BARD1 that includes the RING domain (Wu et al., 1996) . To determine whether this property of BARD1 has been maintained during mammalian evolution, a corresponding segment of murine Bard1 (residues 20 ± 134) was tested for interaction with BRCA1 using a mammalian version of the two-hybrid assay (Fields and Song, 1989 ; Dang Figure 2 The expression patterns of Bard1 and Brca1 in selected tissues of adult mice. A Northern ®lter of polyadenylated RNA from dierent mouse tissues (2 mg mRNA/lane) was hybridized sequentially with radiolabeled probes of mouse Bard1 (a), mouse Brca1 (b) and human GAPDH (c) cDNAs according to the manufacturer's instructions (Clontech). The probes were comprised of cDNA sequences from mouse Bard1, mouse Brca1 [pE18; Bennett et al., 1995] , and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively. As shown, elevated levels of Brca1 and Bard1 transcripts are found in spleen and testes (lanes 3 and 8, respectively), but not in heart (lane 1), brain (lane 2), lung (lane 4), liver (lane 5), skeletal muscle (lane 6) or kidney (lane 7). The mobilities and sizes (in kilobases) of the electrophoretic markers are indicated on the left of each autoradiogram Figure 3 Mammalian two-hybrid analysis of the in vivo interaction of BRCA1 with the mouse and human counterparts of BARD1. Each culture of 293 cells was transiently cotransfected with the G5E1bLUC reporter plasmid and the two indicated expression vectors. The GAL4 expression vector encoded either the`parental' GAL4 DNA-binding domain (pCMV-GAL4; denoted by`+' in the GAL4 column), the GAL4-mBard hybrid (residues 20 ± 134 of murine Bard1), or the GAL4-hBARD1 hybrid (residues 26 ± 142 of human BARD1). The VP16 expression vector encoded either the parental VP16 transactivation domain (pVP-FLAG; denoted by`+' in the VP16 column) or a VP16-BRCA1 hybrid containing residues 1 ± 304 of human BRCA1. Duplicate transfections were conducted for each combination of expression plasmids and the normalized luciferase activities obtained from each transfection are illustrated. The expression plasmid encoding GAL4-mBard was constructed by inserting a 0.35 kilobasepair fragment of mouse Bard1 cDNA into the pCMV-GAL4 expression vector (Wu et al., 1996) . The GAL4-hBARD1 and VP16-BRCA1 expression plasmids and the methods for mammalian two-hybrid analysis have been described (Wu et al., 1996; Tsan et al., 1997) The BRCA1-associated RING domain (BARD1) protein T-C Ayi et al et al., 1991; Tsan et al., 1997) . Therefore, cDNA sequences were inserted into pCMV-GAL4 to generate an expression vector encoding GAL4-mBard1, a hybrid protein containing the DNA-binding domain of the yeast GAL4p transcription factor fused to residues 20 ± 134 of murine Bard1. As illustrated in Figure 3 , transfection of 293 embryonal kidney cells with this vector did not induce expression of a GAL4p-responsive reporter plasmid, G5E1bLUC (lane 4). Likewise, G5E1bLUC activation did not occur upon transfection of these cells with a vector encoding VP16-BR304, a hybrid polypeptide comprised of the VP16 transactivation domain fused to the amino-terminal 304 residues of human BRCA1 (lane 1). As expected, G5E1bLUC was strongly induced by co-expression of VP16-BR304 with GAL4-hBARD, a hybrid containing the DNAbinding domain of pGAL4 fused to residues 26 ± 142 of human BARD1 (lane 5) (Wu et al., 1996) . Signi®cantly, however, G5E1bLUC induction was equivalent, if not greater, in cells that co-express VP16-BR304 with the GAL4-mBard hybrid (lane 3). Thus, the ability to interact with BRCA1 is retained in both the human and mouse orthologs of BARD1. The same results were obtained when these segments of BARD1 and BRCA1 were tested for interaction in the yeast two-hybrid assay (data not shown), indicating that the in vivo association of these proteins does not require additional mammalian factors.
The mouse Brcal and Brca2 polypeptides each share less than 60% amino acid identity with their human equivalents. In contrast, other known tumor suppressors maintain much higher levels of sequence conservation, with mouse/human identities that range from 78% (p53) to 98% (NF1) (see Table 1 of Connor et al., 1997b) . The data provided here reveal an amino acid identity of 70.4% between the mouse and human orthologs of Bard1. As expected, sequence conservation is greater within the known protein motifs of BARD1, including the RING domain (86.7% identity), the three ankyrin repeats (90.1%) and the two BRCT domains (79.8%). Previous studies have shown that sequence conservation is also elevated within the RING (98.0% identity) and BRCT (63.7%) sequences of BRCA1 (Abel et al., 1995; Bennett et al., 1995; Lane et al., 1995; Sharan et al., 1995; Szabo et al., 1996) .
At ®rst glance it would appear that the primary sequence of BARD1 is signi®cantly more conserved than that of BRCA1 (70.4% vs 57.0%, respectively). However, a closer inspection reveals that the higher level of sequence conservation displayed by BARD1 is primarily a re¯ection of its smaller size (777 residues of BARD1 vs 1863 residues of BRCA1) and the fact that the de®ned amino acid domains ± such as the RING and BRCT motifs ± constitute a much greater proportion of the full-length BARD1 polypeptide. Thus, when the known protein domains are excluded (i.e., the RING and BRCT sequences of BRCA1, and the RING, ankyrin and BRCT sequences of BARD1), exceptionally low levels of phylogenetic sequence homology are observed in both BRCA1 (55.0% amino acid identity) and BARD1 (61.1% identity). These comparisons suggest that the primary sequences of BRCA1 and BARD1 have diverged at a similar rate during mammalian evolution, consistent with the notion that these polypeptides function as components of the same heteromeric complex.
If the formation of BRCA1/BARD1 heterodimers is required for BRCA1-mediated tumor suppression, then defects in BARD1 may also promote cancer formation, especially within tissues that are aected by loss of BRCA1, such as breast and ovarian epithelia. Upon screening a panel of seemingly sporadic breast, ovarian and endometrial carcinomas, we recently identi®ed three missense mutations in the BARD1 gene: Q564H, V695L and S761N (Hoa Thai et al., 1998) . Each of these mutations appeared to be tumor-associated since it was not detected in more that 300 controls from the general population and, in at least two of the three cases (Q564H and S761N), tumor formation was accompanied by loss of the wild type BARD1 allele. Although the V695L and S761N substitutions arose somatically during tumor development, Q564H was of germline origin. Interestingly, the Q564H patient had three primary carcinomas of the breast, ovary and endometrium, suggesting that BARD1 lesions may confer a predisposition to carcinoma development. It is noteworthy, therefore, that amino acid Q564 resides within a sequence of ®ve residues (NTGQR) that is conserved in the human and mouse BARD1 polypeptides (Figure 1) .
The subnuclear co-localization of BRCA1, BARD1, HsRad51 and possibly BRCA2, as well as the direct protein-protein interactions between BRCA1 and BARD1 on one hand and BRCA2 and HsRad51 on the other, suggest that these polypeptides may be subunits of the same multi-component protein complex. Recent studies also suggest that this complex may function in the cellular response to DNA damage (Connor et al., 1997a; Scully et al., 1997a,b; Patel et al., 1998) . As noted above, the primary sequences of BRCA1, BARD1 and BRCA2 are poorly conserved in mammals (mouse/human identities of *57%, 70% and 58%, respectively) and orthologs of these polypeptides are conspicuously absent from at least one lower eukaryote: the budding yeast S. cerevisiae. In contrast, HsRad51 is stringently conserved in mammals (mouse/ human identity of 98.8%) and functional orthologs of HsRad51 have been found in all free-living species, including prokaryotes (Karlin and Brocchieri, 1996) . In keeping with its ancient roots, HsRad51 is essential for DNA double-strand break repair, as well as for normal DNA recombination during both meiosis and mitosis (reviewed recently in reference Cox, 1997) . It is interesting, therefore, to consider the relationship between HsRad51 and the poorly-conserved polypeptides with which it associates in the BRCA1 nuclear dots of S phase cells. Perhaps BRCA1, BRCA2 and BARD1 emerged during the course of eukaryotic evolution to serve as additional regulatory factors to exert ®ner control over an existing HsRad51 function, such as DNA double-strand break repair. Alternatively, these polypeptides may represent components of a novel pathway in the cellular response to DNA damage that is absent in prokaryotes and lower eukaryotes. If so, then HsRad51, with its re®ned ability to catalyze DNA strand exchange, may have been co-opted to serve ± along with its other functions ± in the BRCA1/2 pathway of tumor suppression. In any case, additional insights into the origins of hereditary breast cancer should emerge from biochemical studies of BRCA1, BRCA2 and their associated proteins.
